bioMerieux

Q3 sales miss; guidance moderated

04/11/25 -"bioMerieux’s Q3 sales fell short of expectations. Organic sales growth was primarily driven by a robust performance in Industrial Applications. However, Clinical Applications, the main ..."

PDF page sample
Pages
61
Language
English
Published on
04/11/25
Download
You may also be interested by these reports :
04/11/25
bioMerieux’s Q3 sales fell short of expectations. Organic sales growth was primarily driven by a robust performance in Industrial Applications. ...
04/11/25
Coloplast delivered mixed Q4 2025 figures, with organic revenue growth of 7% marginally missing consensus. However, strong operational tailwinds ...
04/11/25
Philips’ Q3 profitability exceeded expectations. Comparable top-line growth was driven by robust performance in Personal Health and Connected Care. ...
04/11/25
FMC posted strong Q3 results, driven by cost savings and growth across segments, thereby helping to reiterate the 2025 outlook. Despite the results ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO